PURPOSE: Germline testing (GT) for prostate cancer (PCA) is now central to treatment and hereditary cancer assessment. With rising demand for and shortage of genetic counseling (GC), tools to deliver pretest informed consent across practice settings are needed to improve access to GT and precision care. Here, we report on Evaluation and Management for Prostate Oncology, Wellness, and Risk (EMPOWER), a patient-choice study for pretest video-based genetic education (VBGE) versus GC to inform urgent practice needs. PATIENTS AND METHODS: Men with PCA or at risk for PCA (family history of PCA) were eligible and could choose pretest VBGE or GC. Outcomes included decisional conflict for GT, change in genetics knowledge, satisfaction, and intention to share results with family and/or providers. Descriptive statistics summarized results with counts and percentages for categorical variables and mean ± standard deviation for continuous variables. Data were compared with Fisher's exact, chi-squared, or Wilcoxon two-sample tests. Mean change in genetics knowledge was compared with t tests. The significance level was set a priori at .05. RESULTS: Data on the first 127 participants were analyzed. Characteristics were White (85.8%), bachelor's degree (66.9%), and PCA diagnosis (90.6%). The majority chose VBGE (71%) versus GC (29%; P < .001). No differences were observed in decisional conflict for GT or satisfaction. Cancer genetics knowledge improved in both groups without significant difference (+0.9 VBGE, +1.8 GC, P = .056). Men who chose VBGE had higher intention to share GT results (96.4% VBGE v 86.4% GC, P = .02). Both groups had high rates of GT uptake (VBGE 94.4%, GC 92%). CONCLUSION: A substantial proportion of men opted for pretest VBGE, with comparable patient-reported outcomes and uptake of GT. The results support the use of pretest video to address the critical GC shortage in the precision era.
PURPOSE: Germline testing (GT) for prostate cancer (PCA) is now central to treatment and hereditary cancer assessment. With rising demand for and shortage of genetic counseling (GC), tools to deliver pretest informed consent across practice settings are needed to improve access to GT and precision care. Here, we report on Evaluation and Management for Prostate Oncology, Wellness, and Risk (EMPOWER), a patient-choice study for pretest video-based genetic education (VBGE) versus GC to inform urgent practice needs. PATIENTS AND METHODS: Men with PCA or at risk for PCA (family history of PCA) were eligible and could choose pretest VBGE or GC. Outcomes included decisional conflict for GT, change in genetics knowledge, satisfaction, and intention to share results with family and/or providers. Descriptive statistics summarized results with counts and percentages for categorical variables and mean ± standard deviation for continuous variables. Data were compared with Fisher's exact, chi-squared, or Wilcoxon two-sample tests. Mean change in genetics knowledge was compared with t tests. The significance level was set a priori at .05. RESULTS: Data on the first 127 participants were analyzed. Characteristics were White (85.8%), bachelor's degree (66.9%), and PCA diagnosis (90.6%). The majority chose VBGE (71%) versus GC (29%; P < .001). No differences were observed in decisional conflict for GT or satisfaction. Cancer genetics knowledge improved in both groups without significant difference (+0.9 VBGE, +1.8 GC, P = .056). Men who chose VBGE had higher intention to share GT results (96.4% VBGE v 86.4% GC, P = .02). Both groups had high rates of GT uptake (VBGE 94.4%, GC 92%). CONCLUSION: A substantial proportion of men opted for pretest VBGE, with comparable patient-reported outcomes and uptake of GT. The results support the use of pretest video to address the critical GC shortage in the precision era.
Authors: Adam H Buchanan; Santanu K Datta; Celette Sugg Skinner; Gail P Hollowell; Henry F Beresford; Thomas Freeland; Benjamin Rogers; John Boling; P Kelly Marcom; Martha B Adams Journal: J Genet Couns Date: 2015-04-03 Impact factor: 2.537
Authors: Veda N Giri; Elias Obeid; Sarah E Hegarty; Laura Gross; Lisa Bealin; Colette Hyatt; Carolyn Y Fang; Amy Leader Journal: Prostate Date: 2018-04-14 Impact factor: 4.104
Authors: Channing J Paller; Emmanuel S Antonarakis; Tomasz M Beer; Hala T Borno; Maria I Carlo; Daniel J George; Julie N Graff; Shilpa Gupta; Elisabeth I Heath; Celestia S Higano; Rana R McKay; Alicia K Morgans; Akash Patnaik; Daniel P Petrylak; Matthew B Rettig; Charles J Ryan; Mary-Ellen Taplin; Young E Whang; Jacob Vinson; Heather H Cheng; Veda N Giri Journal: Clin Genitourin Cancer Date: 2019-04-18 Impact factor: 2.872
Authors: Silke Gillessen; Gerhardt Attard; Tomasz M Beer; Himisha Beltran; Anders Bjartell; Alberto Bossi; Alberto Briganti; Rob G Bristow; Kim N Chi; Noel Clarke; Ian D Davis; Johann de Bono; Charles G Drake; Ignacio Duran; Ros Eeles; Eleni Efstathiou; Christopher P Evans; Stefano Fanti; Felix Y Feng; Karim Fizazi; Mark Frydenberg; Martin Gleave; Susan Halabi; Axel Heidenreich; Daniel Heinrich; Celestia Tia S Higano; Michael S Hofman; Maha Hussain; Nicolas James; Ravindran Kanesvaran; Philip Kantoff; Raja B Khauli; Raya Leibowitz; Chris Logothetis; Fernando Maluf; Robin Millman; Alicia K Morgans; Michael J Morris; Nicolas Mottet; Hind Mrabti; Declan G Murphy; Vedang Murthy; William K Oh; Piet Ost; Joe M O'Sullivan; Anwar R Padhani; Chris Parker; Darren M C Poon; Colin C Pritchard; Robert E Reiter; Mack Roach; Mark Rubin; Charles J Ryan; Fred Saad; Juan Pablo Sade; Oliver Sartor; Howard I Scher; Neal Shore; Eric Small; Matthew Smith; Howard Soule; Cora N Sternberg; Thomas Steuber; Hiroyoshi Suzuki; Christopher Sweeney; Matthew R Sydes; Mary-Ellen Taplin; Bertrand Tombal; Levent Türkeri; Inge van Oort; Almudena Zapatero; Aurelius Omlin Journal: Eur Urol Date: 2020-01-27 Impact factor: 20.096
Authors: Anita Y Kinney; Laurie E Steffen; Barbara H Brumbach; Wendy Kohlmann; Ruofei Du; Ji-Hyun Lee; Amanda Gammon; Karin Butler; Saundra S Buys; Antoinette M Stroup; Rebecca A Campo; Kristina G Flores; Jeanne S Mandelblatt; Marc D Schwartz Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: William T Lowrance; Rodney H Breau; Roger Chou; Brian F Chapin; Tony Crispino; Robert Dreicer; David F Jarrard; Adam S Kibel; Todd M Morgan; Alicia K Morgans; William K Oh; Matthew J Resnick; Anthony L Zietman; Michael S Cookson Journal: J Urol Date: 2020-09-22 Impact factor: 7.450
Authors: Chukwuma N Eruchalu; Margaret S Pichardo; Maheetha Bharadwaj; Carmen B Rodriguez; Jorge A Rodriguez; Regan W Bergmark; David W Bates; Gezzer Ortega Journal: J Urban Health Date: 2021-01-20 Impact factor: 3.671
Authors: Wassim Abida; Akash Patnaik; David Campbell; Jeremy Shapiro; Alan H Bryce; Ray McDermott; Brieuc Sautois; Nicholas J Vogelzang; Richard M Bambury; Eric Voog; Jingsong Zhang; Josep M Piulats; Charles J Ryan; Axel S Merseburger; Gedske Daugaard; Axel Heidenreich; Karim Fizazi; Celestia S Higano; Laurence E Krieger; Cora N Sternberg; Simon P Watkins; Darrin Despain; Andrew D Simmons; Andrea Loehr; Melanie Dowson; Tony Golsorkhi; Simon Chowdhury Journal: J Clin Oncol Date: 2020-08-14 Impact factor: 44.544